• Eone Diagnomics Genome Center’s delisting process remains on hold pending resolution of its injunction application challenging the delisting decision.
• The corporate review committee decided to delist the company on Nov. 19, 2025.
• Termination of rehabilitation proceedings, disclosed Nov. 10, 2026, removes some grounds for its designation as a stock under administrative supervision.
• No related market action will be taken; the exchange will proceed once the litigation is resolved.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eone Diagnomics Genome Center Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261110900796), on November 10, 2026, and is solely responsible for the information contained therein.